Evidence map›Paper›PMID 35886043›Full record

Trial reportGenes2022

Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study.

Nicole D Armstrong, Vinodh Srinivasasainagendra, Lakshmi Manasa S Chekka, Nam H K Nguyen, Noor A Nahid, Alana C Jones, Rikki M Tanner, Bertha A Hidalgo, Nita A Limdi, Steven A Claas and 7 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Nicole D ArmstrongDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Vinodh SrinivasasainagendraDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Lakshmi Manasa S ChekkaDivision of Applied Regulatory Sciences, Center for Drug Evaluation and Research, Silver Spring, MD 20903, USA.
Nam H K NguyenDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA.ORCID 0000-0003-3036-4748
Noor A NahidDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA.
Alana C JonesDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Rikki M TannerDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Bertha A HidalgoDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Nita A LimdiDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Steven A ClaasDepartment of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY 40506, USA.ORCID 0000-0001-9789-8395
Yan GongDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA.
Caitrin W McDonoughDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA.
Rhonda M Cooper-DeHoffDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA.ORCID 0000-0002-5198-130X
Julie A JohnsonDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA.
Hemant K TiwariDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Donna K ArnettDepartment of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY 40506, USA.
Marguerite R IrvinDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
University of Alabama at Birmingham · USUniversity of Florida · USUniversity of Kentucky · USCenter for Drug Evaluation and Research · US

Funding

MECHANISMS OF HYPERTENSION AND CARDIOVASCULAR DISEASEST32HL007457 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Martin E Young · 1985 to 2026
$8.6M
Genomic Background of Blood Pressure Response to Thiazide Diuretic in African AmericansR01HL123782 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI IRVIN, MARGUERITE R · 2016 to 2020
$3.7M
INTEGRATIVE DATA APPROACHES FOR RESISTANT HYPERTENSION IDENTIFICATION AND PREDICTIONK01HL141690 · NHLBI · UNIVERSITY OF FLORIDA · PI MCDONOUGH, CAITRIN W · 2018 to 2021
$486k
Genetic and Epigenetic Risk Scores for Chronic Kidney Disease in African AmericansF31DK128990 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JONES, ALANA CHRISTINE · 2021 to 2023
$128k
NHLBI NIH HHS K01 HL141690NHLBI NIH HHS R01 HL123782NHLBI NIH HHS T32 HL007457NIDDK NIH HHS F31 DK128990NIDDK NIH HHS F31DK128990
6 · The paper itself

Abstract

Hypertension is a leading risk factor for cardiovascular disease mortality. African Americans (AAs) have the highest prevalence of hypertension in the United States, and to alleviate the burden of hypertension in this population, better control of blood pressure (BP) is needed. Previous studies have shown considerable interpersonal differences in BP response to antihypertensive treatment, suggesting a genetic component. Utilizing data from 4297 AA participants randomized to chlorthalidone from the Genetics of Hypertension Associated Treatments (GenHAT) study, we aimed to identify variants associated with the efficacy of chlorthalidone. An additional aim was to find variants that contributed to changes in fasting glucose (FG) in these individuals. We performed genome-wide association analyses on the change of systolic and diastolic BP (SBP and DBP) over six months and FG levels over 24 months of treatment. We sought replication in the International Consortia of Pharmacogenomics Studies. We identified eight variants statistically associated with BP response and nine variants associated with FG response. One suggestive

Indexed as

ChlorthalidoneHypertensionBlack or African AmericanGenome-Wide Association StudyGlucoseHumansUnited StatesChlorthalidoneGlucoseantihypertensivesdrug responsepharmacogenomics

Identifiers

PMID35886043
PMCPMC9319619
OpenAlexW4285733789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.